I suspect the tardiness lies with the SEC and not Biocurex. I believe the company has all its documentation ducks in a row, and met all its obligations.
I've been nibbling at the shares while the company is in the nether world of the pinks, and believe that the outlook is still very good. We saw further validation of their tech in yet another cancer just three weeks ago, and independent teams are now conducting additional tests in many diverse domains. But all of this takes time.
I am disappointed that the shares have not done better since April, but this is very much a "lose it all" or "win very big" proposition. The technology is strong, they have THE big-name scientists on board from the cancer marker space, such as Phil Gold, and so far the technical result have been outstanding!
Hang in there, this company is for real.